Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma

G. Nadali, F. Vinante, H. Stein, G. Todeschini, C. Tecchio, L. Morosato, M. Chilosi, F. Menestrina, Marsha C Kinney, J. P. Greer, U. Latza, G. Perona, G. Pizzolo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To determine serum levels of the soluble form of CD30 molecule (sCD30) in patients with Ki-1/CD30+ anaplastic large-cell lymphoma (ALCL), and to evaluate its correlation with clinical features at presentation and its possible role as a tumor marker to monitor response to treatment and subsequent follow-up. Patients and Methods: sCD30 serum levels were measured with an improved commercial sandwich enzyme-linked immunosorbent assay (ELISA) test kit in 24 patients with CD30+ ALCL at diagnosis and in 13 after treatment. Results: Increased values (> 20 U/mL) at diagnosis were observed in 23 of 24 cases (median, 842.5 U/mL; range, 16 to 37,250) as compared with controls (P < .0001). These values were greater than those of 60 stage- matched cases of Hodgkin's disease (HD) (P < .0001). The highest median value was observed in patients with T-cell-type ALCL (1,690 U/mL), with a significant overall difference as compared with B- and null-cell types (P = .004). Phenotype maintained its significance when results were corrected for other parameters, such as age, sex, and stage (P = .03). sCD30 values returned to the normal range in complete remission (CR), but remained increased in one patient who only partially responded to treatment. Subsequent increases of sCD30 levels were recorded in four of four patients after relapse. Conclusion: sCD30 appears to be a new biologic serum tumor marker of possible use in the clinical setting of CD30+ ALCL.

Original languageEnglish (US)
Pages (from-to)1355-1360
Number of pages6
JournalJournal of Clinical Oncology
Volume13
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Tumor Biomarkers
Serum
Null Lymphocytes
Hodgkin Disease
Reference Values
Therapeutics
Biomarkers
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes
Phenotype
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nadali, G., Vinante, F., Stein, H., Todeschini, G., Tecchio, C., Morosato, L., ... Pizzolo, G. (1995). Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. Journal of Clinical Oncology, 13(6), 1355-1360.

Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. / Nadali, G.; Vinante, F.; Stein, H.; Todeschini, G.; Tecchio, C.; Morosato, L.; Chilosi, M.; Menestrina, F.; Kinney, Marsha C; Greer, J. P.; Latza, U.; Perona, G.; Pizzolo, G.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 1995, p. 1355-1360.

Research output: Contribution to journalArticle

Nadali, G, Vinante, F, Stein, H, Todeschini, G, Tecchio, C, Morosato, L, Chilosi, M, Menestrina, F, Kinney, MC, Greer, JP, Latza, U, Perona, G & Pizzolo, G 1995, 'Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1355-1360.
Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. Journal of Clinical Oncology. 1995;13(6):1355-1360.
Nadali, G. ; Vinante, F. ; Stein, H. ; Todeschini, G. ; Tecchio, C. ; Morosato, L. ; Chilosi, M. ; Menestrina, F. ; Kinney, Marsha C ; Greer, J. P. ; Latza, U. ; Perona, G. ; Pizzolo, G. / Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1355-1360.
@article{1b3b044a68ca4ac389f408c6ba569a04,
title = "Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma",
abstract = "Purpose: To determine serum levels of the soluble form of CD30 molecule (sCD30) in patients with Ki-1/CD30+ anaplastic large-cell lymphoma (ALCL), and to evaluate its correlation with clinical features at presentation and its possible role as a tumor marker to monitor response to treatment and subsequent follow-up. Patients and Methods: sCD30 serum levels were measured with an improved commercial sandwich enzyme-linked immunosorbent assay (ELISA) test kit in 24 patients with CD30+ ALCL at diagnosis and in 13 after treatment. Results: Increased values (> 20 U/mL) at diagnosis were observed in 23 of 24 cases (median, 842.5 U/mL; range, 16 to 37,250) as compared with controls (P < .0001). These values were greater than those of 60 stage- matched cases of Hodgkin's disease (HD) (P < .0001). The highest median value was observed in patients with T-cell-type ALCL (1,690 U/mL), with a significant overall difference as compared with B- and null-cell types (P = .004). Phenotype maintained its significance when results were corrected for other parameters, such as age, sex, and stage (P = .03). sCD30 values returned to the normal range in complete remission (CR), but remained increased in one patient who only partially responded to treatment. Subsequent increases of sCD30 levels were recorded in four of four patients after relapse. Conclusion: sCD30 appears to be a new biologic serum tumor marker of possible use in the clinical setting of CD30+ ALCL.",
author = "G. Nadali and F. Vinante and H. Stein and G. Todeschini and C. Tecchio and L. Morosato and M. Chilosi and F. Menestrina and Kinney, {Marsha C} and Greer, {J. P.} and U. Latza and G. Perona and G. Pizzolo",
year = "1995",
language = "English (US)",
volume = "13",
pages = "1355--1360",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma

AU - Nadali, G.

AU - Vinante, F.

AU - Stein, H.

AU - Todeschini, G.

AU - Tecchio, C.

AU - Morosato, L.

AU - Chilosi, M.

AU - Menestrina, F.

AU - Kinney, Marsha C

AU - Greer, J. P.

AU - Latza, U.

AU - Perona, G.

AU - Pizzolo, G.

PY - 1995

Y1 - 1995

N2 - Purpose: To determine serum levels of the soluble form of CD30 molecule (sCD30) in patients with Ki-1/CD30+ anaplastic large-cell lymphoma (ALCL), and to evaluate its correlation with clinical features at presentation and its possible role as a tumor marker to monitor response to treatment and subsequent follow-up. Patients and Methods: sCD30 serum levels were measured with an improved commercial sandwich enzyme-linked immunosorbent assay (ELISA) test kit in 24 patients with CD30+ ALCL at diagnosis and in 13 after treatment. Results: Increased values (> 20 U/mL) at diagnosis were observed in 23 of 24 cases (median, 842.5 U/mL; range, 16 to 37,250) as compared with controls (P < .0001). These values were greater than those of 60 stage- matched cases of Hodgkin's disease (HD) (P < .0001). The highest median value was observed in patients with T-cell-type ALCL (1,690 U/mL), with a significant overall difference as compared with B- and null-cell types (P = .004). Phenotype maintained its significance when results were corrected for other parameters, such as age, sex, and stage (P = .03). sCD30 values returned to the normal range in complete remission (CR), but remained increased in one patient who only partially responded to treatment. Subsequent increases of sCD30 levels were recorded in four of four patients after relapse. Conclusion: sCD30 appears to be a new biologic serum tumor marker of possible use in the clinical setting of CD30+ ALCL.

AB - Purpose: To determine serum levels of the soluble form of CD30 molecule (sCD30) in patients with Ki-1/CD30+ anaplastic large-cell lymphoma (ALCL), and to evaluate its correlation with clinical features at presentation and its possible role as a tumor marker to monitor response to treatment and subsequent follow-up. Patients and Methods: sCD30 serum levels were measured with an improved commercial sandwich enzyme-linked immunosorbent assay (ELISA) test kit in 24 patients with CD30+ ALCL at diagnosis and in 13 after treatment. Results: Increased values (> 20 U/mL) at diagnosis were observed in 23 of 24 cases (median, 842.5 U/mL; range, 16 to 37,250) as compared with controls (P < .0001). These values were greater than those of 60 stage- matched cases of Hodgkin's disease (HD) (P < .0001). The highest median value was observed in patients with T-cell-type ALCL (1,690 U/mL), with a significant overall difference as compared with B- and null-cell types (P = .004). Phenotype maintained its significance when results were corrected for other parameters, such as age, sex, and stage (P = .03). sCD30 values returned to the normal range in complete remission (CR), but remained increased in one patient who only partially responded to treatment. Subsequent increases of sCD30 levels were recorded in four of four patients after relapse. Conclusion: sCD30 appears to be a new biologic serum tumor marker of possible use in the clinical setting of CD30+ ALCL.

UR - http://www.scopus.com/inward/record.url?scp=0029053867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029053867&partnerID=8YFLogxK

M3 - Article

C2 - 7751879

AN - SCOPUS:0029053867

VL - 13

SP - 1355

EP - 1360

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -